Kit and method for predicting drug therapeutic effect of leflunomide at SNP locus

A leflunomide and kit technology, applied in the field of molecular biology and medicine, can solve the problems of increased risk of A allele toxicity and other problems, and achieve the effect of precise drug use

Inactive Publication Date: 2018-07-20
GUANGZHOU HEKANG MEDICAL TECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have confirmed that the A allele of CYP1A2C734A increases the risk of toxic reactions by 9.7 times (P=0.002, OR=9.708, 95%CI=2.276, 41.403)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit and method for predicting drug therapeutic effect of leflunomide at SNP locus
  • Kit and method for predicting drug therapeutic effect of leflunomide at SNP locus
  • Kit and method for predicting drug therapeutic effect of leflunomide at SNP locus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The invention provides a kit, which is aimed at the gene loci of leflunomide drug efficacy and adverse reaction risk in human genomic DNA, that is, DHODH (19C>A), namely rs3213422, and CYP1A2 (734C>A), namely rs762551. Design specific primers and wild-type / mutant probes, hybridize with MagPlex-TAG magnetic beads coupled with corresponding reporter probes, and detect on the luminex 200 instrument through color reaction. The base type of each SNP site is judged by reading the signal value.

[0024] The specific primer sequences involved in the kit are as follows:

[0025]

[0026]

[0027] The specific probe sequences involved are as follows:

[0028]

[0029] The reporter probe sequences involved are as follows:

[0030]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method and a kit for predicting drug therapeutic effect and adverse reaction of leflunomide at a SNP locus and relates to the field of molecular biology and medicines. In order to evaluate the therapeutic effect and the adverse reaction risk of the leflunomide in the use of rheumatoid arthritis and other diseases through detecting single nucleotide polymorphism (SNP) genotypes of a DHODH gene and a CYP1A2 gene closely related to the drug therapeutic effect and the adverse reaction risk of the leflunomide, the invention provides a system for predicting the drug therapeutic effect and the risk of the leflunomide at the SNP locus, which comprises specific sequence primers, specific probes and reporter probes. The method and the kit provided by the invention have the benefits that the specific sequence primers, the specific probes and the reporter probes are provided, a group of gene loci for the drug therapeutic effect and the adverse reaction risk of the leflunomide is innovatively detected, the therapeutic effect and the adverse reaction risk after patients with rheumatoid arthritis and other patients take the leflunomide are predicted, and the precise medication of the patients is facilitated.

Description

technical field [0001] The present invention relates to the fields of molecular biology and medicine. More specifically, the present invention relates to a system and a kit for a group of leflunomide drug curative effect and adverse reaction risk SNP sites, through simultaneous detection of leflunomide drug curative effect and adverse reactions The risk-related single nucleotide polymorphism (SNP) genotypes of DHODH gene and CYP1A2 gene were used to evaluate the efficacy and risk of adverse reactions of leflunomide in rheumatoid arthritis and other diseases. Background technique [0002] Leflunomide is a slow-acting antirheumatic drug (DMARD) for rheumatoid arthritis (RA). Previous clinical trials have confirmed that 30-50% of patients treated with leflunomide achieve a 20% reduction in disease activity (ACR20), and the curative effect is also significant when combined with methotrexate. However, there is still a significant proportion of patients who do not respond to it, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/156
Inventor 杜予和
Owner GUANGZHOU HEKANG MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap